Get the Stockscreener App
8.32
4.70%
-0.41
After Hours:
8.48
0.16
+1.92%
Xencor Inc stock is traded at $8.32, with a volume of 721.32K.
It is down -4.70% in the last 24 hours and up +5.85% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$8.73
Open:
$8.55
24h Volume:
721.32K
Relative Volume:
0.87
Market Cap:
$592.14M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-2.8789
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
-9.96%
1M Performance:
+5.85%
6M Performance:
-54.49%
1Y Performance:
-59.26%
1-Day Range:
$8.31
$8.87
1-Week Range:
$8.31
$9.445
52-Week Range:
$7.16
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
8.32 | 621.32M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Xencor appoints biotech veteran Raymond Deshaies to board of directors - Investing.com Australia
Xencor Appoints Raymond Deshaies to Board of Directors - TipRanks
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors - Yahoo Finance
What is Xencor Inc. company’s growth strategyFree Stock Target Finder That Work - jammulinksnews.com
Xencor’s XmAb819 Study: A Promising Step in Renal Cell Carcinoma Treatment - TipRanks
How volatile is Xencor Inc. stock compared to the marketExpert Picks Outlook For Beginners - jammulinksnews.com
How many analysts rate Xencor Inc. as a “Buy”Smart Portfolio Planner For Beginners - jammulinksnews.com
RSI Reset May Fuel Rebound in Xencor Inc.AI Based High Gain Watchlist Scanner Shared - metal.it
Why Xencor Inc. stock attracts strong analyst attentionTechnical Stock Breakout Predictions Signal Entry Points - metal.it
What is the risk reward ratio of investing in Xencor Inc. stockPowerful profit generation - jammulinksnews.com
Will Xencor Inc. Reverse From Oversold ConditionsROI Driven Equity Selection With Safety Emphasized - beatles.ru
What is the dividend policy of Xencor Inc. stockInvest smarter with advanced market data - jammulinksnews.com
How does Xencor Inc. generate profit in a changing economyFree Stock Chart Pattern Guide - jammulinksnews.com
Moving Average Trends for Xencor Inc. Stock: What They IndicateAnalyst Grade Signals - Newser
Price action breakdown for Xencor Inc.Free Early Breakout Entry Point Notifications - Newser
Signal strength of Xencor Inc. stock in tech scannersValue Investing Checklist with Entry Signals - Newser
Is Xencor Inc. stock overvalued or undervaluedGet exclusive market insights for better trading - jammulinksnews.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Should I hold or sell Xencor Inc. stock in 2025Discover high-impact investment opportunities - jammulinksnews.com
What are Xencor Inc. company’s key revenue driversTremendous growth opportunities - jammulinksnews.com
Xencor Inc. Company’s Quarterly Earnings Growth: What the Numbers SayHigh Yield Opportunities - metal.it
When is Xencor Inc. stock expected to show significant growthOutstanding trading profits - jammulinksnews.com
Is it the right time to buy Xencor Inc. stockBuild a portfolio for long-term financial success - jammulinksnews.com
What makes Xencor Inc. stock price move sharplyLow Risk ROI Maximization - metal.it
Does Xencor Inc. stock pay reliable dividendsHigh Potential Shares - Newser
Insider Selling: Xencor, Inc. (NASDAQ:XNCR) VP Sells $21,244.68 in Stock - 富途牛牛
Bank of New York Mellon Corp Reduces Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Is Xencor Inc. a good long term investmentOver 200% growth - PrintWeekIndia
Xencor Inc. Stock Analysis and ForecastRobust investment performance - PrintWeekIndia
What drives Xencor Inc. stock priceOutstanding investment returns - PrintWeekIndia
How Xencor Inc. stock performs during market volatilityDaily Top Gainers - Newser
What analysts say about Xencor Inc. stockUnmatched profit growth - Autocar Professional
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Arizona State Retirement System - Defense World
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):